Neurocrine Biosciences, Inc. (NBIX) earnings
NBIX earnings moved a median of -1.29% by the close. Quarterly and annual NBIX reports and results, each read against the price at its own news timestamp. Back to the NBIX overview →
30 measured NBIX earnings events.
Where these NBIX earnings landedvs 30 measured NBIX earnings reactions
| Middle 50% of NBIX earnings reactions | -2.94% to +0.66% |
|---|---|
| Median reaction (to close) | -1.29% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 NBIX earnings events with a measured close landed between -2.94% and +0.66%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results | Press release | -0.39% | -3.20% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Jun 30 | SEC filing · Form 10-Q | -6.66% | -9.52% | |
| Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results | Press release | -6.66% | -9.52% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results | Press release | -1.05% | -2.15% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31 | SEC filing · Form 10-Q | -1.68% | -1.20% | |
| Neurocrine Biosciences Reports First-Quarter 2026 Financial Results | Press release | -1.68% | -1.20% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results | Press release | -0.38% | -0.39% | |
| Form 10-K NEUROCRINE BIOSCIENCES For: Dec 31 | SEC filing · Form 10-K | -2.88% | -6.98% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Sep 30 | SEC filing · Form 10-Q | -0.61% | -1.41% | |
| Neurocrine Biosciences Reports Third Quarter 2025 Financial Results | Press release | -0.61% | -1.41% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results | Press release | -0.75% | +0.88% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Jun 30 | SEC filing · Form 10-Q | -5.43% | -6.47% | |
| Neurocrine Biosciences Reports Second Quarter 2025 Financial Results | Press release | -5.43% | -6.47% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results | Press release | -0.11% | +0.21% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31 | SEC filing · Form 10-Q | +2.95% | -3.32% | |
| Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance | Press release | +2.95% | -3.32% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results | Press release | +0.04% | -0.74% | |
| Form 10-K NEUROCRINE BIOSCIENCES For: Dec 31 | SEC filing · Form 10-K | -0.37% | +0.66% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Sep 30 | SEC filing · Form 10-Q | +1.94% | -1.68% | |
| Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance | Press release | +1.94% | -1.68% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results | Press release | -0.45% | +0.65% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Jun 30 | SEC filing · Form 10-Q | +2.96% | +1.94% | |
| Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance | Press release | +2.96% | +1.94% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results | Press release | -0.32% | -0.34% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31 | SEC filing · Form 10-Q | -1.67% | +2.03% | |
| Neurocrine Biosciences Reports First Quarter 2024 Financial Results | Press release | -1.67% | +2.03% | |
| Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results | Press release | -0.02% | -1.52% | |
| Form 10-K NEUROCRINE BIOSCIENCES For: Dec 31 | SEC filing · Form 10-K | +0.54% | -1.38% | |
| Form 10-Q NEUROCRINE BIOSCIENCES For: Sep 30 | SEC filing · Form 10-Q | +2.48% | +4.19% | |
| Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance | Press release | +2.48% | +4.19% |
Keep exploring
More NBIX: analyst actions → · SEC filings → · NBIX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kadmon Holdings, Inc. (KDMN) | 628 | 0.00% | 46% |
| GTX (GTXI) | 623 | 0.00% | 45% |
| Viveve Medical, Inc. (VIVE) | 621 | -0.82% | 38% |
| CHINA BIOLOGIC PRODUCTS (CBPO) | 619 | -0.04% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.